A new analysis from the U.S. National Cancer Institute has found that the rates of brain tumors (glioma) in the United States are inconsistent with the results of Lennart Hardell’s group in Sweden. The NCI team, led by Mark Little, does allow that “the U.S. data could be consistent with the modest excess risks in the Interphone study.’’